ライフサイエンスコーパス: pertuzumab

1 led ((124)I, (125)I) HER2-specific antibody (pertuzumab).

2 umab in a total antibody mass of 20-50 mg of pertuzumab.

3 docetaxel, carboplatin, and trastuzumab plus pertuzumab.

4 the anti-tumor efficacies of trastuzumab and pertuzumab.

5 evant benefit in patients who received prior pertuzumab.

6 ion that received both prior trastuzumab and pertuzumab.

7 eness analysis to assess the value of adding pertuzumab.

8 ost-effectiveness studies of trastuzumab and pertuzumab.

9 locked in cells pretreated with lapatinib or pertuzumab.

10 b alone and in combination with lapatinib or pertuzumab.

11 , including trastuzumab, trastuzumab-DM1 and pertuzumab.

12 usceptibility to the HER2-targeted inhibitor pertuzumab.

13 3%) completed treatment with trastuzumab and pertuzumab.

14 y the therapeutic antibodies trastuzumab and pertuzumab.

15 eased in patients treated with gemcitabine + pertuzumab.

16 to 1.03; P = .07) in favor of gemcitabine + pertuzumab.

17 ent, when exposed to the anti-HER-2 antibody pertuzumab.

18 of docetaxel, carboplatin, trastuzumab, and pertuzumab.

19 umab may detect more lesions than (89)Zr-DFO-pertuzumab.

20 emotherapy with paclitaxel, trastuzumab, and pertuzumab.

21 completed up to 18 cycles of trastuzumab and pertuzumab.

22 ially received two cycles of trastuzumab and pertuzumab.

23 ne assay-reported pCR score with response to pertuzumab.

24 mab, but the mutant complex does not bind to pertuzumab.

25 e is known about the charge heterogeneity of pertuzumab.

26 vs paclitaxel (n = 107) plus trastuzumab and pertuzumab.

27 etion of treatment with both trastuzumab and pertuzumab.

28 ccumulation of membrane-bound (89)Zr-labeled pertuzumab.

29 limits accepted for modified trastuzumab and pertuzumab.

30 patients who progressed on trastuzumab plus pertuzumab.

31 dual-antibody therapy with trastuzumab plus pertuzumab.

32 e agents or a combination of trastuzumab and pertuzumab.

33 cancer were enrolled and administered (89)Zr-pertuzumab.

34 were recruited to a dose-escalation study of pertuzumab (0.5 to 15 mg/kg) given intravenously every 3

35 tients who were randomly assigned to receive pertuzumab (2400 patients) or placebo (2405 patients) ha

36 stuzumab (6 mg/kg; loading dose 8 mg/kg) and pertuzumab (420 mg intravenously; loading dose 840 mg) e

37 pertuzumab (trastuzumab emtansine 3.6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses

38 ng dose --> 6 mg/kg) once every 3 weeks plus pertuzumab (840 mg loading dose --> 420 mg) once every 3

39 dose followed by 6 mg/kg every 3 weeks) and pertuzumab (840 mg loading dose followed by 420 mg every

40 mg/m(2) from cycle 2 if tolerated; group A), pertuzumab (840 mg loading dose, followed by 420 mg ever

41 ased response system, to receive intravenous pertuzumab (840 mg loading dose, followed by 420 mg main

42 Patients received pertuzumab (840 mg loading dose, then 420 mg every 3 wee

43 y assigned to also receive either placebo or pertuzumab (840-mg loading dose followed by 420 mg every

44 r MBC were treated with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequentl

45 Novel combinations include pertuzumab (a HER2 dimerization inhibitor), lapatinib (a

46 rapeutic target, we examined the activity of pertuzumab, a HER2 antibody that inhibits HER3 signaling

47 Pertuzumab, a humanized antibody that prevents HER2 dime

48 Pertuzumab, a recombinant humanized monoclonal antibody

49 Incubation of EAC cells with trastuzumab and pertuzumab accelerated the expression of EMT markers, co

50 hase II feasibility study of trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy (nCRT)

51 e designs were used to evaluate two doses of pertuzumab administered intravenously once every 3 weeks

52 or patients who crossed over from placebo to pertuzumab after the interim analysis.

53 bination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patient

54 Pertuzumab also potentiated the effects of MEK inhibitor

55 Pertuzumab, an anti-HER2 humanized monoclonal antibody t

56 Although pertuzumab, an antibody binding to the dimerization arm

57 Results: Twenty-one patients received pertuzumab and 19 completed at least two cycles.

58 ive-disease-free survival rate of 91.8% with pertuzumab and 89.2% with placebo.

59 of two humanized monoclonal antibodies (mAb) pertuzumab and bevacizumab.

60 Although the median OS in both the pertuzumab and control groups were shorter in this study

61 l of 579 pairs of matched patients receiving pertuzumab and controls were included.

62 B), pertuzumab and trastuzumab (group C), or pertuzumab and docetaxel (group D).

63 rs and can be overcome by the combination of pertuzumab and erdafitinib treatment.

64 abases to identify all patients treated with pertuzumab and T-DM1 following reimbursement approval in

65 o investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HE

66 The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15

67 s) and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab (group C), or pertuzumab and

68 logic complete response (pCR) to neoadjuvant pertuzumab and trastuzumab (PT).

69 ance doses) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1

70 mary endpoint: the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection pr

71 nd superantigen protein A (spA) by using the pertuzumab and trastuzumab IgE models.

72 We aimed to assess the activity of pertuzumab and trastuzumab in patients with HER2-amplifi

73 activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we re

74 The combination of pertuzumab and trastuzumab resulted in a clinical benefi

75 therapy with trastuzumab, the combination of pertuzumab and trastuzumab seems to be more active than

76 study to evaluate the efficacy and safety of pertuzumab and trastuzumab with paclitaxel given once pe

77 A subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyalur

78 tic breast cancer, with the dual blockade of pertuzumab and trastuzumab, with docetaxel, demonstratin

79 the HER2 binding antibodies Trastuzumab and Pertuzumab and two EGFR binding antibodies including Cet

80 peptides based on the binding of HER-2 with pertuzumab and VEGF with VEGFR2.

81 ross-center price ratios ranged between 2.2 (pertuzumab) and 15.8 (leuprolide).

82 d to receive docetaxel plus trastuzumab plus pertuzumab, and 406 patients were assigned to receive do

83 breast cancer who progressed on trastuzumab, pertuzumab, and a taxane were treated with T-DM1 at 3.6

84 Trastuzumab, pertuzumab, and taxane for first-line treatment and T-DM

85 s exposed to the combination of trastuzumab, pertuzumab, and the TGFbeta inhibitor expressed epitheli

86 n mice given the combination of trastuzumab, pertuzumab, and the TGFbeta inhibitor than in mice given

87 cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did no

88 have gained regulatory approval: lapatinib, pertuzumab, and trastuzumab-emtansine.

89 ved six weekly treatments of trastuzumab and pertuzumab; and an ultrasound+antibody group that receiv

90 ti-ERBB1 Mab), trastuzumab (anti-ERBB2 Mab), pertuzumab (anti-ERBB2 Mab), and lapatinib (dual ERBB1 a

91 ed the improvement of bispecific trastuzumab/pertuzumab antibodies interacting simultaneously with tw

92 o HER2-expressing tumors when trastuzumab or pertuzumab are already employed.

93 nt benefit was observed in the gemcitabine + pertuzumab arm compared with the gemcitabine alone arm (

94 reported in one patient in the gemcitabine + pertuzumab arm.

95 ith disease progression continued to receive pertuzumab (at the same dose), with the addition of tras

96 (89)Zr-pertuzumab-avid foci that were suspicious for HER2-posit

97 positive disease, confirming that the (89)Zr-pertuzumab avidity was a true-positive result for HER2-p

98 months with a combination of trastuzumab and pertuzumab became resistant to chemotherapeutic agents (

99 MBC who received T-DM1 after trastuzumab and pertuzumab between March 1, 2013, and July 15, 2015, via

100 ls to determine how HER2 endocytosis affects pertuzumab binding to tumor cells.

101 stant to the HER2 antibodies trastuzumab and pertuzumab but respond to PI3K inhibitor buparlisib (TPB

102 AC cells become resistant to trastuzumab and pertuzumab by activating TGFbeta signaling, which induce

103 h factor receptor 2 (HER2)-specific antibody pertuzumab by substantially reducing their affinity for

104 T-DM1 and pertuzumab can be combined at full doses with no unexpec

105 R2-targeted PET tracer zirconium 89 ((89)Zr)-pertuzumab can depict HER2-positive metastases in women

106 Low HER3 mRNA expression may predict pertuzumab clinical benefit and be a valuable prognostic

107 for their metastatic disease to receive the pertuzumab combination or the placebo combination.

108 3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95

109 ling and cell proliferation than trastuzumab/pertuzumab combinations with similar activity in vivo.

110 13.8% in patients who received gemcitabine + pertuzumab compared with 4.6% in patients who received g

111 uggested prolonged median survival time with pertuzumab compared with historical controls.

112 on of the crystal structure of the HER-2/neu-pertuzumab complex demonstrated that the receptor dimeri

113 oncentration (C(trough); ie, cycle 8 predose pertuzumab concentration) within the fixed-dose combinat

114 Patients received a loading dose of 840 mg pertuzumab (cycle 1) followed by 420 mg for subsequent c

115 Neither alpha-IR3 nor pertuzumab decreased HER-2 phosphorylation, suggesting t

116 [<1%] of 223 with trastuzumab emtansine plus pertuzumab), diarrhoea (33 [15%] vs 2 [<1%]), and febril

117 The treatment effect of pertuzumab did not differ significantly by stromal TIL v

118 docetaxel, carboplatin, and trastuzumab plus pertuzumab (docetaxel 75 mg/m(2); carboplatin area under

119 the placebo group up to the day before first pertuzumab dose.

120 xel weekly for 12 weeks plus trastuzumab and pertuzumab every 3 weeks for 4 cycles.

121 Patients received pertuzumab every 3 weeks.

122 Tumors exposed to trastuzumab and pertuzumab expressed EMT markers and were poorly differe

123 Pertuzumab extended the median duration of response by 7

124 docetaxel, carboplatin, and trastuzumab plus pertuzumab), fatigue (three [1%] vs seven [3%]), alanine

125 docetaxel, carboplatin, and trastuzumab plus pertuzumab, fewer patients receiving trastuzumab emtansi

126 docetaxel, carboplatin, and trastuzumab plus pertuzumab group (absolute difference -11.3 percentage p

127 had not been reached (95% CI 42.4-NE) in the pertuzumab group (hazard ratio 0.66, 95% CI 0.52-0.84; p

128 ebo group and 18.7 months (16.6-21.6) in the pertuzumab group (hazard ratio 0.69, 95% CI 0.58-0.81).

129 l group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death,

130 investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.

131 Median follow-up was 99.9 months in the pertuzumab group (IQR 92.9-106.4) and 98.7 months (90.9-

132 3 patients in the trastuzumab emtansine plus pertuzumab group and 123 (55.7%) of 221 patients in the

133 rence occurred in 171 patients (7.1%) in the pertuzumab group and 210 patients (8.7%) in the placebo

134 urvival rates were 37% (95% CI 31-42) in the pertuzumab group and 23% (19-28) in the placebo group.

135 rvival was 57.1 months (95% CI 50-72) in the pertuzumab group and 40.8 months (36-48) in the placebo

136 sive-disease-free survival were 94.1% in the pertuzumab group and 93.2% in the placebo group.

137 asive-disease-free survival was 97.5% in the pertuzumab group and 98.4% in the placebo group (hazard

138 lyses were not adjusted for crossover to the pertuzumab group and are likely to be conservative.

139 alysis was not adjusted for crossover to the pertuzumab group and is therefore conservative.

140 Five (1%) of 408 patients in the pertuzumab group and six (2%) of 396 patients in the pla

141 im analysis of overall survival favoured the pertuzumab group but was not significant.

142 survival were significantly improved in the pertuzumab group compared with the placebo group.

143 rrhea of grade 3 or above were higher in the pertuzumab group than in the control group.

144 nger median progression-free survival in the pertuzumab group than in the placebo group.

145 rse events in the trastuzumab emtansine plus pertuzumab group were decreased platelet count (three [1

146 docetaxel, carboplatin, and trastuzumab plus pertuzumab group were neutropenia (55 [25%] of 219 vs on

147 vent suggestive of congestive heart failure (pertuzumab group) and one new symptomatic left ventricul

148 pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time

149 acebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001),

150 eutropenia (200 [49%] of 408 patients in the pertuzumab group, 183 [46%] of 396 patients in the place

151 asive-disease-free survival was 92.0% in the pertuzumab group, as compared with 90.2% in the placebo

152 red in the chemotherapy plus trastuzumab and pertuzumab group.

153 he placebo group and 113 (28%) of 402 in the pertuzumab group.

154 50 patients crossed from the placebo to the pertuzumab group.

155 atients receiving trastuzumab emtansine plus pertuzumab had a grade 3-4 adverse event (29 [13%] of 22

156 Pertuzumab has no clinically significant single-agent ac

157 Although pertuzumab has some activity in patients with HER2-posit

158 argeted blockade (trastuzumab emtansine plus pertuzumab); however, numerically more grade 3-4 and ser

159 f not previously administered) and may offer pertuzumab, if the patient has not previously received i

160 nRIalpha-, Her2-, and spA-binding regions of pertuzumab IgE, with implications for use of IgE/anti-Ig

161 ients underwent PET/CT with 74 MBq of (89)Zr-pertuzumab in a total antibody mass of 20-50 mg of pertu

162 all survival was significantly improved with pertuzumab in an interim analysis without the median bei

163 eeks of starting treatment with single-agent pertuzumab in castrate patients with hormone-refractory

164 sess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC

165 antibody group that received trastuzumab and pertuzumab in combination with six weekly sessions of BB

166 PFS benefits for docetaxel, trastuzumab, and pertuzumab in first-line treatment, and the EMILIA trial

167 xel cohorts, meriting further exploration of pertuzumab in ovarian cancer.

168 e assay-reported pCR score and the effect of pertuzumab in pCR was observed.

169 group analyses showed trends in PFS favoring pertuzumab in the gemcitabine and paclitaxel cohorts, me

170 patients treated with trastuzumab emtansine/pertuzumab in the I-SPY2 trial, but not in the trastuzum

171 to be a similar significant OS benefit with pertuzumab in the real-world setting.

172 Biomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (former

173 f biomarkers that would predict benefit from pertuzumab in this setting.

174 etaxel plus trastuzumab (TH) with or without pertuzumab in US patients with metastatic breast cancer.

175 ed agents, trastuzumab emtansine (T-DM1) and pertuzumab, in patients with HER2-positive metastatic br

176 Pertuzumab increases the rate of pathological complete r

177 Pertuzumab inhibited ligand-dependent morphogenesis in t

178 Pertuzumab injection was followed 8 h later by the deliv

179 and PET were performed at 24 and 48 h after pertuzumab injection.

180 Pertuzumab is a humanized monoclonal antibody that inhib

181 Pertuzumab is an anti-HER2 antibody, and its binding to

182 plete response) and suggest that neoadjuvant pertuzumab is beneficial when combined with trastuzumab

183 xel given once per week with trastuzumab and pertuzumab is highly active and well tolerated and seems

184 Pertuzumab is well tolerated with a RR of 4.3% in heavil

185 These results demonstrate that pertuzumab is well tolerated, has a pharmacokinetic prof

186 nation with anti-EGFR (RG7160) or anti-HER2 (pertuzumab) mAbs.

187 Pertuzumab may add activity to gemcitabine for the treat

188 (89)Zr-ss-pertuzumab may detect more lesions than (89)Zr-DFO-pertu

189 In addition, pertuzumab-mediated inhibition of ErbB2 heterodimerizati

190 of 28 IgA1s and A2s of both Trastuzumab and Pertuzumab models.

191 val was longer with combination therapy than pertuzumab monotherapy (17.4 v 7.1 weeks, respectively).

192 All 29 patients enrolled for pertuzumab monotherapy experienced disease progression.

193 BR were 3.4% and 10.3%, respectively, during pertuzumab monotherapy.

194 umab to patients whose disease progressed on pertuzumab monotherapy.

195 nt trastuzumab (n = 765) in combination with pertuzumab (n = 328), lapatinib (n = 187) or without a s

196 docetaxel, carboplatin, and trastuzumab plus pertuzumab (n=221).

197 nt treatment with trastuzumab emtansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastu

198 me regimen with a matching placebo replacing pertuzumab (n=406).

199 Pertuzumab (Omnitarg) is a humanized mAb directed agains

200 Trastuzumab (herceptin) and pertuzumab (Omnitarg, 2C4) are recombinant humanized mon

201 2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting

202 to receive either trastuzumab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab pl

203 ve, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemoth

204 Pertuzumab or placebo and trastuzumab were given until d

205 Patients were assigned to receive either pertuzumab or placebo at a loading dose of 840 mg, and 4

206 2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and doc

207 ase 3 study comparing the addition of either pertuzumab or placebo to first-line therapy with trastuz

208 cer treated with docetaxel, trastuzumab, and pertuzumab or placebo, higher TIL values are significant

209 cer treated with docetaxel, trastuzumab, and pertuzumab or placebo, higher TIL values are significant

210 onoclonal antibodies such as trastuzumab and pertuzumab, or small scaffold proteins such as affibody

211 patients who have progressed on trastuzumab, pertuzumab, or trastuzmab emtansine, given its differenc

212 patients who have progressed on trastuzumab, pertuzumab, or trastuzmab emtansine, given its differenc

213 nti-HER antibody treatment (ie, trastuzumab, pertuzumab, or trastuzumab emtansine) planned for 12 mon

214 e positives on (89)Zr-trastuzumab and (89)Zr-pertuzumab PET scans were reclassified as HER2-low.

215 evaluated the safety and dosimetry of (89)Zr-pertuzumab PET/CT for human epidermal growth factor rece

216 Trials.gov NCT02286843) and underwent (89)Zr-pertuzumab PET/CT for noninvasive whole-biopsy evaluatio

217 breast cancers and brain metastases, (89)Zr-pertuzumab PET/CT suggested that the brain metastases we

218 Six women demonstrated foci at (89)Zr-pertuzumab PET/CT that were suspicious for HER2-positive

219 2 (HER2)-targeted imaging with zirconium 89-pertuzumab PET/CT was successful in detecting HER2-posit

220 potential clinical applications of (89)Zr-ss-pertuzumab PET/CT.

221 successful HER2-targeted imaging with (89)Zr-pertuzumab PET/CT.

222 specific antibodies based on trastuzumab and pertuzumab plant biosimilars (bi-TPB-PPB).

223 stuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL

224 ab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in

225 to 1.11; P = .14; median PFS, 4.3 months for pertuzumab plus chemotherapy v 2.6 months for placebo pl

226 utaneous formulation compared to intravenous pertuzumab plus trastuzumab in patients with HER2-positi

227 erum C(trough) concentrations to intravenous pertuzumab plus trastuzumab in the neoadjuvant setting w

228 or subcutaneous injection versus intravenous pertuzumab plus trastuzumab in the per-protocol pharmaco

229 Dual HER2-targeted therapy with pertuzumab plus trastuzumab is well tolerated and could

230 rastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab g

231 The combination of pertuzumab plus trastuzumab plus docetaxel, as compared

232 l survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel.

233 d; neoadjuvant chemotherapy (paclitaxel plus pertuzumab plus trastuzumab): n = 149, neoadjuvant chemo

234 ab): n = 149, neoadjuvant chemotherapy-free (pertuzumab plus trastuzumab, trastuzumab-only)/antibody-

235 2-targeting antibodies (i.e. trastuzumab and pertuzumab) prolong survival in HER2-positive breast can

236 Pertuzumab represents a new class of targeted anticancer

237 Pertuzumab represents a new class of targeted therapeuti

238 The addition of pertuzumab resulted in an additional 1.81 life-years gai

239 docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted in significantly more patients achi

240 oading dose, 6 mg/kg maintenance doses) plus pertuzumab [same dosing as in the other group]).

241 eous injection provides non-inferior cycle 7 pertuzumab serum C(trough) concentrations to intravenous

242 The geometric mean ratio of pertuzumab serum C(trough) subcutaneous to serum C(troug

243 endpoint was non-inferiority of the cycle 7 pertuzumab serum trough concentration (C(trough); ie, cy

244 Pertuzumab significantly improved the rates of invasive-

245 ATRA (Clinical Evaluation of Trastuzumab and Pertuzumab) study demonstrated superior progression-free

246 and the addition of the second HER2 antibody pertuzumab substantially increases the magnitude of this

247 ring chemotherapy and was more frequent with pertuzumab than with placebo (9.8% vs. 3.7%).

248 Diarrhea was more common with pertuzumab than with placebo.

249 Among the cohort of patients who received pertuzumab, the median (IQR) OS and time on treatment wa

250 ia in Solid Tumors after 1.5 and 6 months of pertuzumab therapy, and lasted for 11 and 10 months, res

251 Adding pertuzumab to chemotherapy did not significantly improve

252 ed phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-res

253 -month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-l

254 Addition of trastuzumab and pertuzumab to nCRT in patients with HER2-positive EAC is

255 ve metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared wit

256 d breast cancer and also suggest that adding pertuzumab to trastuzumab may augment therapeutic benefi

257 nical trials have shown that the addition of pertuzumab to trastuzumab-based chemotherapy for first-l

258 s) of neoadjuvant trastuzumab emtansine plus pertuzumab (trastuzumab emtansine 3.6 mg/kg; pertuzumab

259 een treatment groups, and in line with other pertuzumab, trastuzumab, and chemotherapy trials.

260 ase were randomly assigned to receive either pertuzumab, trastuzumab, and docetaxel (n=402) or the sa

261 ificant improvement in overall survival with pertuzumab, trastuzumab, and docetaxel in patients with

262 NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a signific

263 served improvements in overall survival with pertuzumab, trastuzumab, and docetaxel versus placebo, t

264 g-term safety and cardiac safety profiles of pertuzumab, trastuzumab, and docetaxel were maintained i

265 study to compare the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, tra

266 3 study comparing the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, tra

267 docetaxel and 148 (36%) of 408 who received pertuzumab, trastuzumab, and docetaxel, and included feb

268 antly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with

269 e ready-to-use, fixed-dose combination vial (pertuzumab, trastuzumab, and hyaluronidase-zzxf) was app

270 m suggested that survival was prolonged with pertuzumab treatment, compared with historic controls wi

271 al, clinicopathological characteristics, and pertuzumab treatment.

272 Lovastatin-enhanced pertuzumab tumor uptake was also observed in NCI-N87 gas

273 of HER2 endocytosis as a strategy to improve pertuzumab uptake in HER2-positive gastric tumors and al

274 These engineered pertuzumab variants show increased lysosomal delivery an

275 s showed a slightly increased sensitivity to pertuzumab versus parental cells.

276 tuzumab VH3 interacted with spA, none of our pertuzumab VH variants, including VH3, associated with s

277 ere found between IgE and omalizumab for the pertuzumab VH variants.

278 Pertuzumab VH1-VH7 family variants of IgE with the same

279 The pertuzumab VH5 IgE variant, but not the trastuzumab VH5

280 (89)Zr-pertuzumab was able to image multiple sites of malignanc

281 ree survival (PFS) and overall survival when pertuzumab was added to trastuzumab and docetaxel.

282 Pertuzumab was conjugated with deferoxamine and radiolab

283 NBC), and trastuzumab biosimilar ABP980 plus pertuzumab was given in ERBB2-positive BC (ERBB2-positiv

284 d a NHB of 13.8 QALMs versus strategy C when pertuzumab was included in strategy C.

285 The effect on PFS favoring pertuzumab was more pronounced in the gemcitabine and pa

286 validated the model using experiments where pertuzumab was used to block HER2 dimerization.

287 Pertuzumab was well tolerated and resulted in no objecti

288 Pertuzumab was well tolerated with diarrhea in 69.1% (11

289 Pertuzumab was well tolerated.

290 Pertuzumab was well tolerated; diarrhea was the most com

291 Importantly, these activities of pertuzumab were distinct from those of trastuzumab, a mo

292 The pharmacokinetics of pertuzumab were similar to other humanized immunoglobuli

293 ation of two classes of drugs (cisplatin and pertuzumab) when delivered by these two alternative rout

294 In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemo

295 umab (an inhibitor of HER2), with or without pertuzumab (which inhibits dimerization of HER2 with HER

296 In contrast, the HER2 antibody pertuzumab, which blocks HER2 heterodimerization, inhibi

297 vity of T-DM1 in patients who received prior pertuzumab, which is now included as standard first-line

298 of 6 mg/kg on day 1, as well as intravenous pertuzumab with a loading dose of 840 mg and a maintenan

299 estimate progression-free survival (PFS) of pertuzumab with gemcitabine in patients with platinum-re

300 ited a third cohort of patients who received pertuzumab without trastuzumab.